The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer

被引:6
|
作者
Bragina, Olga D. [1 ,2 ]
Deyev, Sergei M. [2 ,3 ]
Chernov, Vladimir, I [1 ,2 ]
Tolmachev, Vladimir M. [2 ,4 ]
机构
[1] Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Tomsk 634009, Russia
[2] Natl Res Tomsk Polytech Univ, Tomsk 634050, Russia
[3] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia
[4] Uppsala Univ, Uppsala, Sweden
来源
ACTA NATURAE | 2022年 / 14卷 / 02期
关键词
breast cancer; HER2/neu; radionuclide diagnostics; monoclonal antibody; alternative scaffold proteins; HER2; EXPRESSION; THERAPEUTIC TARGETS; RECEPTOR; THERANOSTICS; TRASTUZUMAB; DISCORDANCE; CONCORDANCE; METASTASES; BIOMARKERS; GUIDELINES;
D O I
10.32607/actanaturae.11611
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This review examines the evolution of the radionuclide diagnosis of HER2-positive breast cancer using various compounds as a targeting module in clinical practice: from full-length antibodies to a new group of small synthetic proteins called alternative scaffold proteins. This topic is of especial relevance today in view of the problems attendant to the detection of breast cancer with HER2/neu overexpression, which, in most cases, introduce errors in the treatment of patients. The results of clinical studies of radiopharmaceuticals based on affibody molecules, ADAPTs, and DARPins for SPECT and PET have demonstrated good tolerability of the compounds, their rapid excretion from the body, and the possibility to differentiate tumor sites depending on the HER2/neu status. This indicates that targeted radionuclide diagnosis holds promise and the need to continue research in this direction.
引用
收藏
页码:4 / 15
页数:12
相关论文
共 50 条
  • [1] Targeted Therapy in HER2-Positive Breast Cancer
    Thill, Marc
    Kraft, Clayton
    Friedrich, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (05) : 295 - 302
  • [2] Targeted therapy in HER2-positive breast cancer (Review)
    Li, Shu Guang
    Li, Li
    BIOMEDICAL REPORTS, 2013, 1 (04) : 499 - 505
  • [3] Emerging Targeted Therapies for HER2-Positive Breast Cancer
    Florencia Mercogliano, Maria
    Bruni, Sofia
    Luciana Mauro, Florencia
    Schillaci, Roxana
    CANCERS, 2023, 15 (07)
  • [4] Dual HER2-targeted approaches in HER2-positive breast cancer
    Ahn, Eugene R.
    Vogel, Charles L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) : 371 - 383
  • [5] Dual HER2-targeted approaches in HER2-positive breast cancer
    Eugene R. Ahn
    Charles L. Vogel
    Breast Cancer Research and Treatment, 2012, 131 : 371 - 383
  • [6] 131I-Labeled Anti-HER2 Nanobody for Targeted Radionuclide Therapy of HER2-Positive Breast Cancer
    Zhao, Lingzhou
    Gong, Jiali
    Qi, Qinli
    Liu, Changcun
    Su, Hongxing
    Xing, Yan
    Zhao, Jinhua
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2023, 18 : 1915 - 1925
  • [7] Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review
    Schramm, Amelie
    De Gregorio, Nikolaus
    Widschwendter, Peter
    Fink, Visnja
    Huober, Jens
    BREAST CARE, 2015, 10 (03) : 173 - 178
  • [8] Exploring Targeted Therapy for HER2-Positive Metastatic Breast Cancer
    Terrie, Yvette C.
    US PHARMACIST, 2022, 47 (10) : 34 - 39
  • [9] HER2-positive breast cancer
    Loibl, Sibylle
    Gianni, Luca
    LANCET, 2017, 389 (10087): : 2415 - 2429
  • [10] Mechanisms of Resistance to HER2-Targeted Therapies in HER2-positive Breast Cancer
    Veeraraghavan, Jamunarani
    Liao, Fu-Tien
    Qin, Lanfang
    Gordon, Tia
    Raghavan, Alekya
    Sabotta, Caroline
    Kaplan, Rachel
    Gutierrez, Carolina
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    Schiff, Rachel
    CANCER RESEARCH, 2024, 84 (03)